Phase 2 COPD Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are at least 12 years old at the time of signing the consent form.
• People who are able to understand and are willing to sign a written consent form; for those aged 12 to 17, a parent or guardian must also provide consent.
• People of Chinese background who have received a stem cell transplant from a donor and who have chronic graft-versus-host disease (cGVHD) — a condition where the donated cells attack the body — that is active, not responding to treatment, or has come back, and that requires ongoing immune-suppressing medication after trying steroids and at least one other treatment.
• People who have both an ongoing acute form and a chronic form of graft-versus-host disease at the same time (sometimes called "overlap syndrome").
• People who have a general health and functioning score of 60 or above on the relevant scale for their age group, indicating they are able to carry out some daily activities (confirm with trial site).
• People whose blood counts and organ function — including white blood cells, platelets, liver, and kidney measures — fall within the acceptable ranges tested in the 14 days before starting the study treatment.
• People who are already taking steroid medications, as long as the dose has been stable for at least 2 weeks before starting the study treatment.
• People who are already taking certain immune-suppressing medications (CNIs or mTOR inhibitors), as long as the dose has been stable and within the appropriate range for at least 2 weeks before starting the study treatment.
• People who are willing to use appropriate contraception and avoid pregnancy or fathering children during the study and for a set period after the last dose of study treatment.

Who may not be able to join:

• People who have the acute form of graft-versus-host disease only, with no signs of the chronic form.
• People who show any signs that their original cancer has returned, or who have developed a transplant-related lymph gland disease, at the time of screening.
• People with a history of acute or chronic inflammation of the pancreas (pancreatitis).
• People who currently have active, symptomatic muscle inflammation (myositis).
• People with a history of serious illness, an uncontrolled infection, an allergy to ingredients in the study drug, or any other condition that the study doctor believes would make participation unsafe.
• People who are HIV positive.
• People with a history of active or latent tuberculosis (TB), recent close contact with someone who has active TB, or a positive TB blood test at screening.
• People with active hepatitis B or hepatitis C infection requiring treatment, or those at risk of hepatitis B reactivation based on specific blood test results at screening.
• People diagnosed with another cancer (other than the one for which the transplant was done) within the past 3 years, unless it was fully treated with the intent to cure and approved by the study's medical oversight team.
• People who are pregnant or breastfeeding.
• People who have previously received a treatment that targets a specific protein called CSF-1R.
• People who have used any cGVHD treatment other than steroids, CNIs, or mTOR inhibitors within 2 weeks (or 5 half-lives of that medication, whichever is shorter) before starting the study treatment.
• People who have taken part in another experimental treatment study within 28 days before starting the study treatment.
• People who are currently taking part in any other treatment-based clinical study.

Important: Always verify eligibility with the trial site directly before applying.